Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FT538 + trastuzumab
- Development stage
- Unknown
- Lead developer
- Fate Therapeutics
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
FT538 + trastuzumab is a combination therapy consisting of **FT538**, a multiplexed-engineered, off-the-shelf natural killer (NK) cell therapy derived from clonal induced pluripotent stem cells (iPSCs), and **trastuzumab**, a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2). FT538 incorporates three synthetic modifications: high-affinity, non-cleavable CD16 Fc receptor for enhanced antibody-dependent cellular cytotoxicity (ADCC) in synergy with monoclonal antibodies; an interleukin-15/IL-15 receptor fusion to promote cell persistence without exogenous cytokine support; and CD38 knockout to improve metabolic fitness and resistance to tumor microenvironment stress. Trastuzumab binds HER2 on tumor cells, triggering immune-mediated cytotoxicity and blocking survival signaling. The combination is being investigated for enhanced anti-tumor activity, particularly in HER2-positive solid tumors, where FT538 enhances trastuzumab-mediated ADCC[1][3].
- Other names
- FT538 + trastuzumab
02
Targets
IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)CD38 (Cluster of Differentiation 38)FCGR3B (Fc gamma receptor III)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on FT538 + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FT538 + trastuzumab.